FDA unanimously shuts down Nektar’s opioid painkiller

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Tero Vesalainen)
(Image: Getty/Tero Vesalainen)

Related tags: Fda, Nektar, Opioid, Opioid epidemic

The US FDA’s advisory committee voted 27-0 against recommending approval of oxycodegol, with Nektar deciding to withdraw its application as a result.

According to reporting by Reuters​, the unanimous decision against the drug resulted from concerns over the potential for abuse of the opioid painkiller, oxycodegol. As well as this, Nektar Therapeutic chose to submit data to US Food and Drug Administration (FDA) based on only one pivot efficacy study rather than two studies.

After the rejection, Nektar released a statement outlining its ‘disappointment’ in the decision and that it would withdraw its new drug application (NDA), ending its investment in the development program.

With funding cut from the drug candidate, the company noted that it would look to make cost savings of between $75m (€67.2m) and $125m (€112m) in 2020, based on the estimated expense of commercialization and post-approval studies.

The share price of Nektar has dropped 16% since the advisory committee’s recommendation was made, despite the positive news the company announcement last week on its extended collaboration agreement​ with Bristol-Myers Squibb.

The decision on oxycodegol comes as the FDA moots various measures​ to limit the risk of harm posed by opioid painkillers, amid the ongoing opioid epidemic in North America that has resulted in a number of lawsuits targeting manufacturers.

Related news

Show more

Related products

show more

From Candidate to Clinic- European Capabilities

From Candidate to Clinic- European Capabilities

Catalent Pharma Solutions | 22-Oct-2018 | Technical / White Paper

Catalent’s Nottingham, UK facility focuses on early stage development of small molecule drug candidates from the bench to clinic. This facility offers...

Related suppliers

Follow us

Products

View more

Webinars